Ery Swab
NDC Package 45802-962-72

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Ery (erythromycin) swabs is a medication used to treat acne. This formulation utilizes a swab delivery system. Marketed by Padagis Israel Pharmaceuticals Ltd, this product is identified by NDC 45802-962 and is authorized under FDA application ANDA064126.

Identification & Billing

NDC Package Code
45802-962-72
Package Description
60 APPLICATOR in 1 JAR / .8 mL in 1 APPLICATOR
Product Code
11-Digit Billing Format
45802096272
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ery
Non-Proprietary Name
Erythromycin
Substance Name
Erythromycin
Dosage Form
Swab - A small piece of relatively flat absorbent material that contains a drug. A swab may also be attached to one end of a small stick. A swab is typically used for applying medication or for cleansing.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Usage Information
This medication is used to treat acne. It helps to reduce the number of pimples. Erythromycin is an antibiotic (macrolide-type). It works by stopping the growth of bacteria. This product contains a large amount of alcohol, which dries extra oils from the skin.

Regulatory & Marketing

Labeler Name
Padagis Israel Pharmaceuticals Ltd
Product Type
Human Prescription Drug
FDA Application #
ANDA064126
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-07-2008
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 45802-962-72 identifies a specific commercial package of 60 applicator in 1 jar / .8 ml in 1 applicator of Ery, a human prescription drug labeled by Padagis Israel Pharmaceuticals Ltd. This swab is formulated for topical use and contains erythromycin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Padagis Israel Pharmaceuticals Ltd on July 07, 2008. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat acne. It helps to reduce the number of pimples. Erythromycin is an antibiotic (macrolide-type). It works by stopping the growth of bacteria. This product contains a large amount of alcohol, which dries extra oils from the skin.

How is this Padagis Israel Pharmaceuticals Ltd product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 45802096272. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
45802-962-72
11-Digit CMS (5-4-2)
45802-0962-72

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.